Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Intec Pharma Ltd. (NTEC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/06/2021 8-K Quarterly results
07/29/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Intec Announces $30 Million Private Placement Ahead of Decoy Merger"
07/23/2021 8-K Other Events  Interactive Data
07/16/2021 8-K Other Events  Interactive Data
06/22/2021 8-K Quarterly results
04/30/2021 8-K Acquisition/merger/asset purchase announced
Docs: "AGREEMENT AND PLAN OF MERGER AGREEMENT AND PLAN OF MERGER, dated as of April 27, 2021, by and between Intec Pharma Ltd., an Israeli company , Intec Parent, Inc., a Delaware corporation and Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Intec Parent , all having their registered offices in 12 Hartom Street Har Hotzvim, Jerusalem, 9777512 Israel. Intec Israel, Intec Parent and Domestication Merger Sub are each referred to herein as a “Party” and collectively as the “Parties”."
03/15/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
12/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma JERUSALEM - Intec Pharma Ltd. today announces it has entered into a feasibility agreement with GW Research Limited , London, U.K. to explore using the Accordion Pill platform for an undisclosed research program. “We are very excited to collaborate with GW,” said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “Through partnerships such as this, we continue to evaluate the utility of our Accordion Pill platform in the development of innovative therapeutics.” Additional details of the agreement were not disclosed. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’ s Accordion Pill..."
11/05/2020 8-K Quarterly results
Docs: "Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update JERUSALEM - Intec Pharma Ltd. today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update. “We maintain our focus on executing strategic partnerships and collaborations. As such, we were delighted in recent weeks to announce a new research collaboration with Merck. While we are unable to provide the specifics of the agreement, it speaks to Merck’ s keen understanding of the Accordion Pill technology and their continued interest in working with us to realize its potential,” stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “In addition, we continue to innovate and progress our next generation gastric retentive techn..."
10/29/2020 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "ARTICLES OF ASSOCIATION, AS AMENDED ON OCTOBER 29, 2020",
"Intec Pharma Announces 1-for-20 Reverse Share Split JERUSALEM - Intec Pharma Ltd. today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020, and the Company’ s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on October 30, 2020 under the Company’ s existing symbol “NTEC.” The Company’ s ordinary shares have been assigned a new CUSIP number of M53644148 in connection with the reverse share split. As previously disclosed, at the Company’ s Annual Meeting of Shareholders held on July 15, 2020, the Company's shareholders approved a proposal to amend the Company’ s Articles of Association to effect a ..."
10/08/2020 8-K Quarterly results
10/02/2020 8-K Quarterly results
09/18/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/10/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/17/2020 8-K Quarterly results
06/08/2020 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
05/11/2020 8-K Quarterly results
Docs: "Intec Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update JERUSALEM - Intec Pharma Ltd. today announces financial results for the first quarter ended March 31, 2020 and provides a corporate update. Highlights from the Quarter and Recent Weeks"
05/06/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
02/03/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between the Company and H.C. Wainwright & Co., LLC",
"Form of Warrant",
"Form of Pre-Funded Warrant",
"Opinion of Meitar | Law Offices",
"Opinion of McDermott Will & Emery LLP"
12/11/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Intec Pharma Provides Update on Novartis Feasibility and Option Agreement Jerusalem – Intec Pharma Ltd. today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill for a proprietary Novartis compound, despite the AP having met the technical and pharmacokinetic clinical specifications set forth by Novartis. Novartis, following an internal and revised commercial strategic assessment, advised Intec that this program no longer meets Novartis’ mid to long-term strategic goals. Novartis agreed to pay Intec Pharma $1.5 million USD on conclusion of the program. This project was originally announced in January 2018. Under the terms of the agreement, the drug and therapeutic area were not disclosed. “While we are disa..."
12/03/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Opinion of Meitar Liquornik Geva Leshem Tal, Israeli legal counsel to the Registrant",
"Ordinary Shares Purchase Agreement, between Intec Pharma Ltd. and Aspire Capital Fund, LLC",
"Registration Rights Agreement, between Intec Pharma Ltd. and Aspire Capital Fund, LLC",
"Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement with Aspire Capital"
12/02/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/12/2019 8-K Quarterly results
09/27/2019 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
09/16/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/09/2019 8-K Quarterly results
09/05/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
08/09/2019 8-K Quarterly results
Docs: "Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update Jerusalem – Intec Pharma Ltd. today announces financial results for the three and six months ended June 30, 2019. Highlights of the second quarter 2019 and recent weeks include:"
07/22/2019 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "ACCORDANCE Study Presentation",
"Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson’ s Disease Patients"
05/07/2019 8-K Quarterly results
Docs: "Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update JERUSALEM – Intec Pharma Ltd. today announces financial results for the three months ended March 31, 2019 and provides a corporate update. Highlights of the first quarter 2019 and recent weeks include: ● Announced that the last patient completed their final visit in the Company’ s pivotal Phase 3 trial evaluating the safety and efficacy of the Accordion Pill-Carbidopa/Levodopa compared with immediate release CD/LD as a treatment for the symptoms of advanced Parkinson’ s disease ; ● Reported positive data from a pharmacokinetic study of AP-CD/LD 50/500 mg in PD patients, demonstrating that AP-CD/LD when dosed three times per day met the primary endpoint of reducing plasma levodopa variability when co..."
04/05/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Intec Pharma Ltd. Compensation Policy, as amended"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy